AVANT CEO to Present at the 28th Annual Canaccord Adams Global Growth Conference
August 08 2008 - 4:16PM
Business Wire
AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that
Anthony S. Marucci, interim President and Chief Executive Officer
of AVANT Immunotherapeutics, Inc., will present at the 28th Annual
Canaccord Adams Global Growth Conference at the InterContinental
Hotel in Boston on Wednesday, August 13 at 4:00 pm, EDT. A live
webcast of the company presentation will be available in the
Investor Information area of AVANT�s website at
http://www.avantimmune.com. An archive of the webcast will be
available via AVANT�s website following the event. About AVANT
Immunotherapeutics, Inc. AVANT Immunotherapeutics, Inc. is a
NASDAQ-listed company discovering and developing innovative
vaccines and targeted immunotherapeutics for the treatment of
cancer, infectious and inflammatory diseases. AVANT focuses on the
use of tumor-specific targets and human monoclonal antibodies
(mAbs) to precisely deliver therapeutic agents through its novel
�targeted immunization� approach. In addition, AVANT is also
exploiting its access to proprietary human antibody technology for
development of therapeutics monoclonal antibodies (mAbs). AVANT�s
deep product pipeline consists of products in varying stages of
development, with its lead candidate, CDX-110, partnered with
Pfizer, Inc., currently undergoing evaluation in a Phase 2/3
clinical trial in newly diagnosed glioblastoma multiforme, one of
the most aggressive forms of brain cancer. AVANT also has five
product candidates in its development pipeline including: CDX-1307,
a product based on its proprietary APC Targeting Technology�, which
is in two Phase 1 clinical trials for patients with advanced
pancreatic, bladder, breast and colon cancer; TP10, a complement
inhibitor, in development for transplantation and other
indications; and Three candidates based on its oral,
rapidly-protecting, single-dose and temperature-stable vaccine
technology, including combination vaccines for travelers, the
military and global health needs. AVANT licensed a rotavirus strain
to GlaxoSmithKline that was used in the development of Rotarix� for
the prevention of rotavirus infection. In addition, AVANT has two
human food safety vaccines for reducing salmonella infection in
chickens and eggs which have been commercialized. Additional
information on AVANT Immunotherapeutics, Inc. can be obtained
through its site on the World Wide Web: http://www.avantimmune.com.
Avant Immunotherapeutics (MM) (NASDAQ:AVAN)
Historical Stock Chart
From Apr 2024 to May 2024
Avant Immunotherapeutics (MM) (NASDAQ:AVAN)
Historical Stock Chart
From May 2023 to May 2024